Orchestra BioMed Holdings Inc. Cash Flow-to-Debt Ratio
Orchestra BioMed Holdings Inc. cash flow-to-debt ratio. Orchestra BioMed Holdings Inc. (OBIO) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2026, meaning its operating cash flow of $-19.33 Million could theoretically repay 0% of its total liabilities ($86.28 Million) in one year. Check OBIO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Orchestra BioMed Holdings Inc. (2020–2025)
Cash flow-to-debt ratio of Orchestra BioMed Holdings Inc. from 2020 to 2025. Historical debt coverage capacity for Orchestra BioMed Holdings Inc. across 6 annual periods. Also explore Orchestra BioMed Holdings Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Orchestra BioMed Holdings Inc. Cash Flow-to-Debt Ratio by Year (2020–2025)
Orchestra BioMed Holdings Inc. cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Orchestra BioMed Holdings Inc.. For the full cash flow conversion analysis, see Orchestra BioMed Holdings Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.95x | $-48.96 Million | $51.48 Million | ▲ +18.7% |
| 2024 | -1.17x | $-50.56 Million | $43.22 Million | ▲ +31.1% |
| 2023 | -1.70x | $-46.13 Million | $27.17 Million | ▼ -149.5% |
| 2022 | -0.68x | $-29.29 Million | $43.04 Million | ▼ -196.9% |
| 2021 | -0.23x | $-19.43 Million | $84.76 Million | ▲ +24.2% |
| 2020 | -0.30x | $-26.18 Million | $86.63 Million | — |